Metformin vs Pioglitazone
Written by Aaron CuhaReviewed Sep 2026
The short answer
Two old diabetes pills with odd second lives in longevity research. Pioglitazone has real heart outcome data and a boxed warning for heart failure. In the 2026 mouse study, it was the only drug that shortened female lifespan, in the analysis that held up after one odd test site was removed.
- Metformin people
- 489
- Metformin nulls
- 0
- Pioglitazone people
- 9,114
- Pioglitazone nulls
- 1
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved as Actos for type 2 diabetes. It carries a boxed warning, the FDA's strongest, for congestive heart failure. Not approved for any ageing or longevity use.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
MetforminMetformin hydrochloride (biguanide)
A cheap, very safe diabetes drug that many people take hoping to live longer. Big studies in people have not shown it helps with ageing. It also takes the edge off the muscle and fitness you gain from training.
Column B
PioglitazonePioglitazone (Actos), thiazolidinedione PPAR-gamma agonist
An approved diabetes drug with real heart and stroke data in people. In the 2026 mouse lifespan run, it was one of two compounds that shortened female lifespan in the check that held up after leaving out an odd lab.
Side by side, on the facts we can check
| What we compare | Metformin | Pioglitazone |
|---|---|---|
| Category | Longevity | Metabolic |
| FDA status | FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity. | FDA-approved as Actos for type 2 diabetes. It carries a boxed warning, the FDA's strongest, for congestive heart failure. Not approved for any ageing or longevity use. |
| Half-life | 4 to 9 hours (plasma), longer in erythrocytes | Three to seven hours for the parent compound, with active metabolites extending to roughly 16 to 24 hours, which supports once-daily dosing. |
| Molecular weight | 129.2 Da (165.6 Da as hydrochloride) | 356.4 Da. A small molecule, not a peptide. |
| How it works | It blocks part of the energy machinery in mitochondria, called complex I, and switches on AMPK, a fuel sensor. That makes the liver release less sugar and helps the body respond to insulin. The AMPK story is not the whole answer. Research groups still argue over how much comes from complex I, from another enzyme called mitochondrial glycerophosphate dehydrogenase, and from effects in the gut. | Pioglitazone switches on PPAR-gamma, a control switch inside cells found mostly in fat tissue. That makes new small fat cells that respond well to insulin. It moves fat out of the liver and muscle, and lowers free fatty acids in the blood. That is how it makes the whole body more sensitive to insulin. The same switch makes the kidney hold on to salt, which causes the swelling and the heart failure risk. It also pushes stem cells in the bone marrow to become fat instead of bone, the likely route to the broken bone risk. |
| Studies in people | 7 | 2 |
| Evidence | Moderate: 3 completed trials, 489 people given it | Strong: 2 completed trials, 9,114 people given it |
| Legal status, US | Prescription only; approved for type 2 diabetes | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Metformin and Pioglitazone?
Metformin: A cheap, very safe diabetes drug that many people take hoping to live longer. Big studies in people have not shown it helps with ageing. It also takes the edge off the muscle and fitness you gain from training. Pioglitazone: An approved diabetes drug with real heart and stroke data in people. In the 2026 mouse lifespan run, it was one of two compounds that shortened female lifespan in the check that held up after leaving out an odd lab.
Which has stronger research evidence, Metformin or Pioglitazone?
Each compound gets a band worked out from facts we counted, with the math shown. Metformin is Moderate (3 completed trials, 489 people given it). Pioglitazone is Strong (2 completed trials, 9,114 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Metformin and Pioglitazone FDA-approved?
Metformin: FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.. Pioglitazone: FDA-approved as Actos for type 2 diabetes. It carries a boxed warning, the FDA's strongest, for congestive heart failure. Not approved for any ageing or longevity use..
Related posts
Blog articles that cover Metformin or Pioglitazone, newest first.
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.